Equities

MaxCyte Inc

MXCT:LSE

MaxCyte Inc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)297.00
  • Today's Change2.00 / 0.68%
  • Shares traded2.49k
  • 1 Year change-22.86%
  • Beta--
Data delayed at least 20 minutes, as of May 02 2024 17:07 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year MaxCyte Inc's revenues fell -6.72% from 44.26m to 41.29m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 23.57m to a larger loss of 37.92m.
Gross margin88.51%
Net profit margin-91.85%
Operating margin-116.98%
Return on assets-13.67%
Return on equity-15.60%
Return on investment-14.54%
More ▼

Cash flow in USDView more

In 2023, MaxCyte Inc increased its cash reserves by 320.30%, or 35.44m. Cash Flow from Investing totalled 54.98m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 21.69m for operations while cash generated from financing totalled 2.14m.
Cash flow per share-0.3268
Price/Cash flow per share--
Book value per share2.23
Tangible book value per share2.23
More ▼

Balance sheet in USDView more

MaxCyte Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 46.51m.
Current ratio10.65
Quick ratio9.97
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.